Surge in China's Outlicensing Deals Signals Growing Global Pharmaceutical Partnerships

In the first two months of 2023, Chinese drug makers have significantly increased their outlicensing activities, with total deal values reaching approximately US$52 billion across 41 transactions. This surge is highlighted by two major agreements: Sino Biopharmaceutical's deal with France's Sanofi, valued at up to US$1.53 billion, and Antengene Corporation's agreement with Belgium's UCB, worth around US$1.18 billion. Analysts indicate that these developments reflect China's emergence as a key source of drug candidates for multinational pharmaceutical companies, which are now favoring long-term partnerships over one-off arrangements.

South China Morning Post

The current pace of outlicensing deals marks a notable increase compared to previous years. In 2022, China recorded a total of 157 deals worth a combined US$135.7 billion, setting a high benchmark for subsequent activities. The recent transactions have already outpaced any single quarter from last year in both upfront payments and total value, indicating a robust trend in cross-border pharmaceutical collaborations.

South China Morning Post

Yang Huang, head of China healthcare research at JPMorgan Chase, emphasizes that the recent agreements are indicative of a broader shift in the pharmaceutical landscape, where global companies are increasingly looking to China for innovative drug candidates. This trend is expected to continue as the industry anticipates signals of government support for innovative drug development during China's "two sessions," although analysts predict that such support may be limited to moral encouragement rather than substantial policy changes.

South China Morning Post

Despite the positive outlook, some industry observers express concerns regarding the sustainability of this growth. Critics argue that while the current surge in outlicensing deals is promising, it may not be indicative of long-term stability in the Chinese pharmaceutical market. They caution that reliance on foreign partnerships could expose domestic companies to vulnerabilities, particularly if global market dynamics shift.

South China Morning Post

Sino Biopharmaceutical announced that its Chia Tai Tianqing Pharmaceutical unit has granted Sanofi exclusive worldwide rights to develop, manufacture, and sell rovadicitinib, an oral drug aimed at treating blood cancer and immune-related diseases. This agreement is part of a broader strategy to enhance collaboration with international partners, reflecting the company's commitment to expanding its global footprint.

South China Morning Post

• “The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion.” — Yang Huang, Head of China Healthcare Research, JPMorgan Chase

South China Morning Post

• “The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said.” — Industry Analyst

South China Morning Post

As the year progresses, the pharmaceutical industry will be closely monitoring the outcomes of these agreements and any potential government initiatives that may arise from the "two sessions." The ongoing evolution of China's role in the global pharmaceutical market will likely shape future strategies for both domestic and international companies.

South China Morning Post